These press releases are for business and financial media.
-
- 27 March 2001
- ASTRAZENECA INVESTS $109 MILLION IN NEW FACILITIES AT CHESHIRE RESEARCH AND DEVELOPMENT CENTRE AstraZeneca is investing $109 million (over £70 million) for new laboratories and office accommodation at its major research and development site at Alderley Park in Cheshire, UK.
-
- 20 March 2001
- ASTRAZENECA PRESENTS NEW PHASE III CRESTOR DATA CONFIRMING EXCITING POTENTIAL AstraZeneca today presents Phase III clinical trial results of its superstatin, Crestor (rosuvastatin - previously known as ZD4522), at the American College of Cardiology (ACC), in Orlando, Florida. The data show that:
-
- 05 March 2001
- ASTRAZENECA PLANS EXPANSION OF JAPANESE BUSINESS BASE WITH $47m INVESTMENT AstraZeneca today showed commitment to continuing to expand its business base in Japan by announcing plans to invest 5.5bn yen ($47m) in manufacturing and distribution facilities.
-
- 28 February 2001
- ASTRAZENECA COMPLETES SALE OF CORBY PACKAGING PLANT AstraZeneca today announced it has completed the sale of its packaging plant at Corby, Northants, to PCI Services, of the US.
-
- 23 February 2001
- ASTRAZENECA COMPLETES DEAL TO BUY CONTROLLING STAKE IN ASTRA-IDL LTD. AstraZeneca today announced it has completed a transaction to buy a controlling stake in Astra-IDL, based in Bangalore, India.
-
- 21 February 2001
- FDA APPROVES ASTRAZENECA's NEXIUM™ WITH COMPREHENSIVE SET OF INDICATIONS London - AstraZeneca confirms it will launch Nexium™ during March in the US, following its approval by the US Food and Drug Administration (FDA) and the announcement of the catalogue price to wholesalers.
-
- 20 February 2001
- SWEDISH PATENT COURT UPHOLDS ASTRAZENECA OMEPRAZOLE SPC AstraZeneca today announced that the Swedish Court of Patent Appeal has ruled that one of the company's Supplementary Protection Certificates (SPC) in Sweden for omeprazole, the active ingredient in Losec®, has not expired. The SPC expires in February, 2003.
-
- 14 February 2001
- ASTRAZENECA GAINS FDA APPROVAL FOR ZOMIG FAST MELT FORMULATION AstraZeneca today announced that it has gained approval from the US Food and Drug Administration (FDA) for its fast melt formulation of Zomig for the treatment of acute migraine in adults.
-
- 08 February 2001
- ASTRAZENECA FULL YEAR RESULTS 2000 View the narrative (Adobe document, 39KB) and figures (Adobe document, 45KB.)
-
- 06 February 2001
- FDA APPROVES ASTRAZENECA'S TOPROL-XL® FOR HEART FAILURE AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved Toprol-XL® (metoprolol CR/XL) extended-release tablets for the treatment of stable, symptomatic (New York Heart Association Class II or III) heart failure of ischemic, hypertensive or cardiomyopathic origin. In a landmark clinical trial, Toprol-XL® has been shown to decrease the rate of mortality plus hospitalisation, largely through a reduction in cardiovascular mortality and hospitalisation for heart failure. The
-
- 01 February 2001
- ASTRAZENECA & IBM SIGN GLOBAL STRATEGIC OUTSOURCING AGREEMENT WORTH $1.7 billion One of the world's largest pharmaceuticals companies - AstraZeneca - and IBM, the world's largest information technology company, today announced that they had signed a global strategic outsourcing agreement worth $1.7 billion over seven years. The agreement, covering the provision of IT infrastructure services to 45 countries, is the largest of its kind in the pharmaceuticals industry.
-
- 19 January 2001
- ASTRAZENECA SELLS DENTAL LOCAL ANAESTHETIC BUSINESS TO DENTSPLY INTERNATIONAL INC. AstraZeneca announced today its decision to divest its dental range of local anaesthetics to DENTSPLY International, Inc. AstraZeneca's portfolio of dental local anaesthetics includes brand names such as Xylocaine®, Citanest® and Polocaine® /Carbocaine. AstraZeneca will retain the ownership of these local anaesthetic brand names but will license the rights to DENTSPLY for their dental use. DENTSPLY has also acquired full rights to Oraqix -- AstraZeneca's new dental gel for scaling and root planning,
-
- 15 January 2001
- ASTRAZENECA INVESTS OVER $60 MILLION IN EXPANDED PRODUCTION FACILITIES FOR 'SEROQUEL' AstraZeneca is investing $60 million (over £37 million) at its manufacturing site in Macclesfield, Cheshire, UK, to meet the rapid growth in global demand for 'Seroquel', the atypical antipsychotic.
-
- 09 January 2001
- GENERIC CHALLENGE TO LOSEC® WITHDRAWN IN CANADA AstraZeneca today announced that the Canadian Federal Court has ordered that the proceedings against Genpharm Inc are deemed to be withdrawn, following the earlier rejection of a regulatory application by Genpharm for generic omeprazole, thus rendering the court proceedings moot.
-
- 04 January 2001
- SYMBICORT® GAINS EUROPEAN UNION MUTUAL RECOGNITION APPROVAL FOR ASTHMA CONTROL AstraZeneca announced today that Symbicort®, a new and innovative treatment for asthma, has been granted approval through the Mutual Recognition Procedure (MRP) in 14 European Union (EU) states plus Norway and Iceland. This follows initial approval of Symbicort in Sweden in August 2000. Sweden acted as the reference member state for the MRP application. In addition to these approvals, Symbicort has been approved in Switzerland, and applications have been submitted in both Canada and Australia.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At Nov 21, 2009 10:43 AM GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
